Telix Pharmaceuticals and Oncidium Bring Prostate Cancer Imaging to the Next Level with NOBLE Registry Results
Advancements in Prostate Cancer Imaging: The NOBLE Registry
In a significant stride towards enhancing the landscape of prostate cancer diagnostics, Telix Pharmaceuticals Limited and the Oncidium Foundation have unveiled groundbreaking findings from their NOBLE Registry. This global real-world evidence study focuses on the TLX599-CDx, an innovative imaging agent designed for prostate cancer detection and has recently been detailed in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports.
Understanding the NOBLE Registry
The NOBLE Registry, aptly named
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.